Amgen tackles rheumatoid arthritis with third biosimilar

You are here: Home > Biotech > Current Article

Amgen tackles rheumatoid arthritis with third biosimilar to get FDA OK

By Marissa Nall / Friday, December 13th, 2019 / Comments Off on Amgen tackles rheumatoid arthritis with third biosimilar to get FDA OK

Thousand Oaks biotech giant Amgen entered a crowded field with its rheumatoid arthritis biosimilar Avsola, where it will tussle with three competitors for some $6 billion in annual sales. The move is the latest in its biosimilar strategy, playing to the biotech giant’s strength in the anti-inflammatory field and targeting newer patients in a growing…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.